Virtu KCG Holdings’s Amicus Therapeutics FOLD Stock Holding History

Virtu KCG Holdings’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-66,066	Closed	-$471K	–	3066
2017 Q1	$471K	Buy	66,066 +743	+1%	+$4.7K	0.01%	1433
2016 Q4	$325K	Buy	65,323 +51,165	+361%	+$354K	0.01%	1991
2016 Q3	$105K	Sell	14,158 -42,190	-75%	-$285K	﹤0.01%	2621
2016 Q2	$308K	Buy	56,348 +41,844	+288%	+$293K	0.01%	1853
2016 Q1	$123K	Buy	+14,504	New	+$103K	﹤0.01%	2272
2015 Q2	–	Sell	-19,098	Closed	-$208K	–	3456
2015 Q1	$208K	Buy	+19,098	New	+$168K	﹤0.01%	2355
2014 Q4	–	Sell	-59,244	Closed	-$352K	–	3887
2014 Q3	$352K	Buy	+59,244	New	+$310K	0.01%	2128
2014 Q1	–	Sell	-19,080	Closed	-$45K	–	3679
2013 Q4	$45K	Sell	19,080 -7,005	-27%	-$15.4K	﹤0.01%	3620
2013 Q3	$61K	Buy	+26,085	New	+$65.5K	﹤0.01%	3476

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtu KCG Holdings's FOLD Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Amicus Therapeutics (FOLD) in Q2 2017, closing a stake of 66,066 shares — an estimated $471K sold.

Virtu KCG Holdings first reported a position in FOLD in Q3 2013 and held it in 9 quarters. The position peaked at $471K in Q1 2017. 141 funds tracked by Wall St. Rank hold FOLD as of Q2 2017.

Virtu KCG Holdings reported no remaining Amicus Therapeutics position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 66,066 Amicus Therapeutics shares in Q2 2017, an estimated $471K.
Virtu KCG Holdings first reported a position in Amicus Therapeutics in Q3 2013 and held it in 9 quarters.
Virtu KCG Holdings's Amicus Therapeutics position peaked at $471K in Q1 2017.
141 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.